**Conflict of interest**

The author declares no conflict of interest.

## **Author details**

Andre Luis Maion Casarim School of Medical Sciences, Universidade Estadual de Campinas, Campinas, Brazil

\*Address all correspondence to: andre.casarim@yahoo.com.br

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**79**

*Parathyroid Glands and Hyperparathyroidism: A General Overview*

disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney International [Internet]. 2017;**92**(5):1217-1222. DOI: 10.1016/j.kint.2017.05.003

[11] Mihai R. Parathyroid disease and calcium metabolism. British Journal of Anaesthesia [Internet]. 2000;**85**(1): 29-43. DOI: 10.1093/bja/85.1.29

[12] Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. The Journal of Clinical Investigation.

[13] Lacativa PGS, Patrício Filho PJM, Gonçalves MDC, De FMLF. Indicações

hiperparatireoidismo secundário à insuficiência renal crônica. Arquivos Brasileiros de Endocrinologia e Metabologia. 2003;**47**(6):644-653

[15] Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: An observational study. International Urology and Nephrology [Internet]. 2019;**51**(7):1261-1270. DOI: 10.1007/

[16] Pitt SC, Panneerselvan R, Chen H, Sippel RS. Secondary and tertiary

1996;**97**(11):2534-2540

de paratireoidectomia no

[14] Cozzolino M, Galassi A, Conte F, Mangano M, Di Lullo L, Bellasi A. Treatment of secondary hyperparathyroidism: The clinical utility of etelcalcetide. Therapeutics and Clinical Risk Management [Internet]. 2017;13:679-689. DOI: 10.2147/TCRM. S108490. Available from: http://www. embase.com/search/results?subaction= viewrecord&from=export&id=L61660

1782%0A

s11255-019-02175-5

*DOI: http://dx.doi.org/10.5772/intechopen.92785*

[1] Gonçalves MDC, Rodrigues ASS. Cirurgia do hiperparatireoidismo. Revista do Colégio Brasileiro de Cirurgiões. 2002;**29**(3):166-176

**References**

[2] Potts J. Chemistry and physiology of parathyroid hormone. Clinical Endocrinology. 1976;**5**:307-315

[3] Vermeulen AHM. The birth of endocrine pathology: How Erdheim misunderstood parathyroids. Virchows

[4] Johansson H. The Uppsala anatomist Ivar Sandström and the parathyroid gland. Upsala Journal of Medical Sciences. 2015;**120**(2):72-77

[5] Sethi N, England JA. Parathyroid surgery: From inception to the modern

day. British Journal of Hospital Medicine. 2017;**78**(6):333-337

2016;**43**(3):214-222

bmj.3.5615.395

[6] Toneto MG, Prill S, Debon LM, Furlan FZ, Steffen N. A história da cirurgia das paratireoides. Revista do Colégio Brasileiro de Cirurgiões.

[7] Davies DR, Dent CE, Watson L. Tertiary hyperparathyroidism. British Medical Journal. 17 August 1968;**3**(5615):395-399. DOI: 10.1136/

Hammond W, Park O. Autonomous secondary (renal) parathyroid

hyperplasia. The New England Journal of Medicine. 1994;**330**(4):242-248

[9] Basile C, Lomonte C. The function of the parathyroid oxyphil cells in uremia: Still a mystery? Kidney International [Internet]. 2017;**92**(5):1046-1048. DOI:

[8] McPhaul J, McIntodh D,

10.1016/j.kint.2017.06.024

[10] Ritter C, Miller B, Coyne DW, Gupta D, Zheng S, Brown AJ, et al. Paricalcitol and cinacalcet have

Archiv. 2010;**457**(3):283-290

*Parathyroid Glands and Hyperparathyroidism: A General Overview DOI: http://dx.doi.org/10.5772/intechopen.92785*
